Skip to main content

Site notifications

ESTALIS 140/50 norethindrone acetate and estradiol 140/50 mcg/day transdermal therapeutic system (Canada)

Section 19A approved medicine
ESTALIS 140/50 norethindrone acetate and estradiol 140/50 mcg/day transdermal therapeutic system (Canada)
Section 19A approval holder
Medsurge Healthcare Pty Ltd ABN 92 124 728 892
Phone
1300 788 261
Approved until
Status
Current
Medicines in short supply/unavailable
ESTALIS CONTINUOUS 50/140 estradiol 50mcg/day norethisterone acetate 140mcg/day patch sachet - ARTG 70813
Indication(s)

For the short-term treatment of symptoms of estrogen deficiency in menopausal women who have an intact uterus.

Images
Picture of Estalis 140-50 transdermal therapeutic system Canada - label

Help us improve the Therapeutic Goods Administration site